Boardroom Alpha
Boardroom Alpha
DCOY · Additional Proxy Materials (DEFA14A) · Filed December 19, 2025

Decoy Therapeutics Inc — Additional Proxy Materials (DEFA14A)

Form
DEFA14A
Filed
December 19, 2025
Ticker
DCOY
Accession
0001615219-25-000198
Boardroom Alpha · Filing insights

Salarius hires Alliance Advisors to solicit proxies for the 2025 meeting; company will pay about $21,000 plus expenses.

About Decoy Therapeutics Inc
Market cap
$5M
1Y TSR
−96.0%
3Y TSR
−85.8%
Board grade
D
Sector
Healthcare
CEO
Frederick E Pierce
Last annual meeting: Feb 24, 2026 · View full Decoy Therapeutics Inc profile →
Document

UNITED STATES
SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549

SCHEDULE 14A

Proxy Statement Pursuant to Section 14(a) of the
Securities Exchange Act of 1934
Filed by the Registrant  ☒ 
Filed by a Party other than the Registrant  ☐
Check the appropriate box:
Preliminary Proxy Statement
Confidential, for Use of the Commission Only (as permitted by Rule 14a-6(e)(2))
Definitive Proxy Statement
Definitive Additional Materials
Soliciting Material Pursuant to §240.14a-12

Salarius Pharmaceuticals, Inc.

(Name of Registrant as Specified in its Charter)
(Name of Person(s) Filing Proxy Statement, if other than the Registrant)
Payment of Filing Fee (Check the appropriate box):
 
No fee required.
   
Fee paid previously with preliminary materials.
Fee computed on table in exhibit required by Item 25(b) per Exchange Act Rules 14a-6(i)(1) and 0-11.
 (1)Amount Previously Paid:
   
 (2)Form, Schedule or Registration Statement No.:
   
 (3)Filing Party:
   
 (4)Date Filed: 
   




image.jpg
SUPPLEMENT TO THE DEFINITIVE PROXY STATEMENT
FOR THE ANNUAL MEETING OF STOCKHOLDERS
TO BE HELD ON DECEMBER 31, 2025 AT 10:00 AM CENTRAL TIME

This proxy statement supplement, dated December 19, 2025, supplements the definitive proxy statement on Schedule 14A (together with subsequent supplements, the “Proxy Statement”) of Salarius Pharmaceuticals, Inc., a Delaware corporation (the “Company”) that was filed with the Securities and Exchange Commission on November 7, 2025, relating to the Company’s 2025 annual meeting of stockholders initially held on December 19, 2025 and adjourned to December 31, 2025 (the “2025 Annual Meeting”). Except as specifically supplemented by the information contained in this proxy statement supplement, all information set forth in the Proxy Statement remains unchanged.
Proxy Solicitor
Subsequent to filing and mailing the Proxy Statement, the Company engaged Alliance Advisors, LLC (“Alliance”), an independent proxy solicitation and advisory firm, to assist it with the solicitation of proxies for the 2025 Annual Meeting. Alliance may solicit proxies by telephone, email, or mail. The Company has agreed to pay Alliance a fee of approximately $21,000, plus additional fees and expenses, for its services. All costs of soliciting votes in connection with the Proxy Statement have been or will be paid by the Company.

From this filing to the vote

Forecast every director vote the day the proxy files.

Meeting Forecast scores each director up for re-election + every contested situation, rebuilt daily across 6,000+ U.S. public companies. The same model that called the LULU contested proxy lives on every meeting you see here.

Independent — issuer-pays-free, ideology-free, U.S.-owned.

More filings

Other filings from Decoy Therapeutics Inc (DCOY)

Reference

Frequently asked questions

When did Decoy Therapeutics Inc file this DEFA14A?
Decoy Therapeutics Inc (DCOY) filed this Additional Proxy Materials (DEFA14A) with the SEC on December 19, 2025. The accession number assigned by EDGAR is 0001615219-25-000198.
What does a DEFA14A disclose?
DEFA14A is additional definitive proxy soliciting material filed in connection with a shareholder meeting — supplemental letters, slides, or amendments issued after the main proxy statement.
What is the key takeaway from this filing?
Salarius hires Alliance Advisors to solicit proxies for the 2025 meeting; company will pay about $21,000 plus expenses. This is Boardroom Alpha's one-line summary of the additional proxy materials; see the full filing text above for the formal disclosure.
Where can I find Decoy Therapeutics Inc's prior proxy statements on EDGAR?
The SEC EDGAR browser lists every DEFA14A Decoy Therapeutics Inc has filed under CIK 1615219, sortable by date. Use the "View on SEC EDGAR" link in the page header, or browse directly via https://www.sec.gov/cgi-bin/browse-edgar.
Disclaimer

The opinions and information contained herein have been obtained or derived from sources believed to be reliable, but Boardroom Alpha cannot guarantee its accuracy and completeness, and that of the opinions based thereon.

This report contains opinions and is provided for informational purposes only – it does not constitute investment, legal or tax advice. You should not rely solely upon the research herein for purposes of transacting securities or other investments, and you are encouraged to conduct your own research and due diligence, and to seek the advice of a qualified securities professional before you make any investment.

None of the information contained in this report constitutes, or is intended to constitute a recommendation by Boardroom Alpha of any particular security or trading strategy or a determination by Boardroom Alpha that any security or trading strategy is suitable for any specific person. To the extent any of the information contained herein may be deemed to be investment advice, such information is impersonal and not tailored to the investment needs of any specific person.

No representation or warranty, expressed or implied, is made on behalf of Boardroom Alpha as to the accuracy or completeness of the information contained herein. Boardroom Alpha does not accept any liability for any direct, indirect or consequential loss or damage suffered by any person as a result of relying on all or any part of this research and any liability is expressly disclaimed.

Full disclaimer